VM
ANRO icon

Valor Management’s Alto Neuroscience ANRO Stock Holding History

Valor Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-157,038
Closed -$1.68M – 5
2024
Q2 		$1.68M Hold
157,038
– – 0.37% 5
2024
Q1 		$2.41M Buy
+157,038
New +$2.46M 0.5% 4

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Valor Management's ANRO Position: Q3 2024 in Review

Valor Management sold out of Alto Neuroscience (ANRO) in Q3 2024, closing a stake of 157,038 shares — an estimated $1.68M sold.

Valor Management first reported a position in ANRO in Q1 2024 and held it in 2 quarters. The position peaked at $2.41M in Q1 2024. 75 funds tracked by Wall St. Rank hold ANRO as of Q3 2024.

  • Valor Management reported no remaining Alto Neuroscience position as of Q3 2024 after selling out during the quarter.
  • Valor Management sold 157,038 Alto Neuroscience shares in Q3 2024, an estimated $1.68M.
  • Valor Management first reported a position in Alto Neuroscience in Q1 2024 and held it in 2 quarters.
  • Valor Management's Alto Neuroscience position peaked at $2.41M in Q1 2024.
  • 75 funds tracked by Wall St. Rank held Alto Neuroscience as of Q3 2024.

Based on Valor Management's 13F filing for Q3 2024, filed 12 Nov 2024.